Product Description
Mechanisms of Action: SP Inhibitor,HMGB1 Inhibitor,Protease Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Drug Overdose|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PF614-MPAR-102 | P1 |
Recruiting |
Drug Overdose |
2025-09-01 |
|
| MPAR-101 | P1 |
Completed |
Healthy Volunteers |
2023-04-26 |